The Korean Journal of Medicine

  • 제84권5호
  • /
  • Pages.764-768
  • /
  • 2013
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

강직성 척추염 환자에서 Infliximab 투여 후 헤노흐-쇤라인 자색반 1예

Henoch-Sch$\ddot{O}$nlein Purpura in a Patient with Ankylosing Spondylitis after Infliximab Therapy

  • 정우진 (부산대학교 의학전문대학원 내과학교실) ;
  • 남윤정 (부산대학교 의학전문대학원 내과학교실) ;
  • 이승근 (부산대학교 의학전문대학원 내과학교실) ;
  • 김지민 (부산대학교 의학전문대학원 내과학교실) ;
  • 송마가렛 (부산대학교 의학전문대학원 피부과학교실) ;
  • 김문범 (부산대학교 의학전문대학원 피부과학교실) ;
  • 김근태 (고신대학교 의과대학 내과학교실)
  • Jung, Woo-Jin (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Nam, Yoon-Jeong (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Lee, Seung-Geun (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Kim, Ji-Min (Department of Internal Medicine, Pusan National University School of Medicine) ;
  • Song, Margaret (Department of Dermatology, Pusan National University School of Medicine) ;
  • Kim, Moon-Bum (Department of Dermatology, Pusan National University School of Medicine) ;
  • Kim, Geun-Tae (Department of Internal Medicine, Kosin University College of Medicine)
  • 투고 : 2012.08.16
  • 심사 : 2012.11.07
  • 발행 : 2013.05.01
⟨ 이전 논문 다음 논문 ⟩

초록

저자들은 강직성 척추염 환자에서 infliximab을 사용한 이후 발생한 헤노흐-쇤라인 자색반을 진단하고 약제 중단 및 스테로이드 요법으로 재발 없이 성공적으로 치료하였기에 문헌고찰과 함께 보고하는 바이다.

Tumor necrosis factor alpha (TNF-${\alpha}$) inhibitors are used widely to treat patients with active rheumatoid arthritis and ankylosing spondylitis (AS). Although various cutaneous reactions can occur as side effects of TNF-${\alpha}$ inhibitors, systemic vasculitis requiring withdrawal of the agent and immunosuppressive drugs is rare. A 59-year-old male with AS who had been treated with infliximab for 60 months visited us with complaints of palpable purpura on both legs and severe abdominal pain. Abdominal computed tomography showed diffuse wall thickening of the proximal jejunum and ileum and a skin biopsy revealed leukocytoclastic vasculitis. The patient was diagnosed with Henoch-Sch$\ddot{O}$nlein purpura (HSP). Infliximab was discontinued and systemic steroid therapy at 0.5 mg/kg resulted in prompt resolution of the HSP. Here, we report the first case of HSP in a patient with AS after infliximab treatment.

키워드

참고문헌

  1. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7: R666-676. https://doi.org/10.1186/ar1724
  2. Lee A, Kasama R, Evangelisto A, Elfenbein B, Falasca G. Henoch-Schonlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol 2006;12:249-251. https://doi.org/10.1097/01.rhu.0000239901.34561.5e
  3. Nobile S, Catassi C, Felici L. Herpes zoster infection followed by Henoch-Schonlein purpura in a girl receiving infliximab for ulcerative colitis. J Clin Rheumatol 2009; 15:101.
  4. Asahina A, Ohshima N, Nakayama H, Shirai A, Juji T, Matsui T. Henoch-Schonlein purpura in a patient with rheumatoid arthritis receiving etanercept. Eur J Dermatol 2010;20:521-522.
  5. Rahman FZ, Takhar GK, Roy O, Shepherd A, Bloom SL, McCartney SA. Henoch-Schonlein purpura complicating adalimumab therapy for Crohn's disease. World J Gastrointest Pharmacol Ther 2010;1:119-122. https://doi.org/10.4292/wjgpt.v1.i5.119
  6. Marques I, Lagos A, Reis J, Pinto A, Neves B. Reversible Henoch-Schonlein purpura complicating adalimumab therapy. J Crohns Colitis 2012;6:796-799. https://doi.org/10.1016/j.crohns.2012.02.019
  7. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004;31:1955-1958.
  8. Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 1990;33: 1114-1121.
  9. Wu SH, Liao PY, Yin PL, Zhang YM, Dong L. Inverse temporal changes of lipoxin A4 and leukotrienes in children with Henoch-Schonlein purpura. Prostaglandins Leukot Essent Fatty Acids 2009;80:177-183. https://doi.org/10.1016/j.plefa.2009.01.008
  10. Ha TS. The role of tumor necrosis factor-alpha in Henoch- Schonlein purpura. Pediatr Nephrol 2005;20:149-153. https://doi.org/10.1007/s00467-004-1726-3

피인용 문헌

  1. Dermatological Side Effects of Anti-tumor Necrosis Factor Alpha Therapy vol.21, pp.1, 2013, https://doi.org/10.4078/jrd.2014.21.1.9
  2. Henoch-Schonlein purpura associated with HLA-B27 positive axial spondyloarthritis in a young man vol.12, pp.5, 2013, https://doi.org/10.1136/bcr-2018-228881